Get to know our clinical trials
Clinical trial to investigate the safety, tolerability, pharmacokinetics and efficacy of TUB-040 in patients with platinum-resistant large malignant ovarian cancer or non-small cell lung cancer.
THE OBJECTIVE OF THIS STUDY IS TO EVALUATE A NEW DRUG (TUB-040) IN TWO PHASES FOR PATIENTS WITH OVARIAN CANCER OR NON-SMALL CELL LUNG CANCER.
Technical Summary
- A FIRST-IN-HUMAN, MULTICENTER, PHASE I/IIA, DOSE-ESCALATION AND DOSE-OPTIMIZATION STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF THE ANTIBODY-DRUG CONJUGATE AGAINST NAPI2B, TUB-040, IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER (PROC) OR NON-SMALL CELL LUNG CANCER (NSCLC) OF THE RECURRENT/REFRACTORY ADENOCARCINOMA TYPE
- Code EudraCT: 2024-511074-80
- Protocol number: NAPISTAR 1-01
- Promoter: Tubulis GmbH
- Molecule/Drug: TUB-040
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.